Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

COSTEM | PTCy versus ATG as haploidentical transplant prophylaxis

Arnon Nagler • 21 Oct 2021
COSTEM
Anti-thymocyte globulin Cyclophosphamide

Arnon Nagler, MD, Chaim Sheba Medical Center, Tel-Aviv, Israel, shares his views on whether post-transplant cyclophosphamide (PTCy) is superior to anti-thymocyte globulin (ATG) as prophylaxis in haploidentical transplant. Prof. Nagler outlines the mechanism of action of PTCy, reporting that it reduces transplanted-related mortality, but comments that further studies are needed to compare it’s efficacy to that of ATG. This interview took place at the 6th Congress on Controversies in Stem Cell Transplantation and Cellular Therapies (COSTEM), which took place virtually.

More from Arnon Nagler

Molecular profiling and MRD are reshaping transplant decision-making in AML
3:19
Molecular profiling and MRD are reshaping transplant decision-making in AML
Arnon Nagler • 15 Jun 2026
EBMT analysis: alloSCT may overcome FLT3-ITD risk in CBFB::MYH11-positive AML
3:26
EBMT analysis: alloSCT may overcome FLT3-ITD risk in CBFB::MYH11-positive AML
Arnon Nagler • 15 Jun 2026
Targeted therapies and immunotherapy are redefining transplantation in AML
3:18
Targeted therapies and immunotherapy are redefining transplantation in AML
Arnon Nagler • 15 Jun 2026
Umbilical cord blood transplantation in adults: revisiting its role in modern practice
2:40
Umbilical cord blood transplantation in adults: revisiting its role in modern practice
Arnon Nagler • 15 Jun 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals